Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check special purpose acquisition company targeting the healthcare and life sciences sector, with a stated focus on businesses at the intersection of translational medicine and commercial development. The SPAC completed its initial public offering in 2021 and filed its most recent annual report on Form 10-K with the SEC on March 30, 2026, under accession number 0001104659-26-036811. As of that filing, TDAC remains a subject of regulatory reporting obligations consistent with its active corporate status. The company's name reflects a thesis oriented toward bridging scientific discovery and scalable healthcare solutions. For complete sponsor details, deal timeline, SEC filing history, and real-time status updates on TDAC, sign up for full data access at SpacDesk.